<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065024</url>
  </required_header>
  <id_info>
    <org_study_id>AGL2012-39503-C02-02</org_study_id>
    <nct_id>NCT02065024</nct_id>
  </id_info>
  <brief_title>Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols</brief_title>
  <acronym>foodmagenpol</acronym>
  <official_title>Food Matrix and Genetic Variability as Determinants of the Bioavailability and Biological Effects of a B-cryptoxanthin and Phytosterols-enriched Beverage; In Vitro and in Vivo Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regular consumption of a beverage containing Î²-cryptoxanthin (b-Cx) and plant sterols (Ps)
      has been shown to exert a synergic effect in reducing cardiovascular risk and bone remodeling
      markers (formation and resorption). The present project aims to assess the influence of
      technological treatment and genetic variability on the bioavailability and the health effects
      of the added components (Ps, b-Cx), in particular to their potential role in prevalent
      disorders.In vitro and in vivo studies will be carried out to this effect. In vitro and in
      vivo studies (human intervention study) will be performed and cardiovascular, bone turnover
      and inflammation markers will be evaluated. Additionally, an in vitro colonic fermentation
      model and cell cultures will be used to explore anticarcinogenic effects and potential
      cytotoxicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum response of B-cryptoxanthin</measure>
    <time_frame>6 weeks of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum response of phytosterols</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum lipid profile</measure>
    <time_frame>6 weks of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone resorption markers</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukins</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive protein</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation markers</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sterols faecal levels</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocytes for eryptosis evaluation</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Intestinal transporters polymorphisms,</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>b-cryptoxanthin plus phytosterols</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fruit and milk based beverage not enriched</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>b-cryptoxanthin plus phytosterols</intervention_name>
    <arm_group_label>b-cryptoxanthin plus phytosterols</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women; mild hypercholesterolemia

        Exclusion Criteria:

          -  Use of cholesterol lowering drugs, hormonal therapy, vitamin and herbs supplements use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Fernando Granado Lorencio</investigator_full_name>
    <investigator_title>dr Fernando Granado Lorencio</investigator_title>
  </responsible_party>
  <keyword>b-cryptoxanthin</keyword>
  <keyword>plant sterols</keyword>
  <keyword>serum Cholesterol</keyword>
  <keyword>bone turnover markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beta-Cryptoxanthin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

